Evidence map›Paper›PMID 27729510›Full record

ArticlemBio2016

Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix.

Eric F Kong, Christina Tsui, Sona Kucharíková, David Andes, Patrick Van Dijck, Mary Ann Jabra-Rizk

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 1 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 1 synthesis or guideline pooled it, 279 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. The metabolic trap:Journal of medical microbiology · 2026
    Article
  7. Article
  8. Article
  9. Copper-driven mutualism ofMicrobiology (Reading, England) · 2026
    Article
  10. Article
  11. Secreted factors ofApplied and environmental microbiology · 2026
    Article
  12. Review
  13. Interactions betweenInfection and immunity · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. The Pathogenicity Mechanisms ofInternational journal of molecular sciences · 2025
    Review
  18. Article
  19. Article
  20. Review

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Eric F KongGraduate Program in Life Sciences, Molecular Microbiology and Immunology Program, University of Maryland, Baltimore, Maryland, USA Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, USA Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, Maryland, USA.
Christina TsuiDepartment of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, Maryland, USA.
Sona KucharíkováLaboratory of Molecular Cell Biology, KU Leuven, Leuven-Heverlee, Flanders, Belgium Department of Molecular Microbiology, VIB, Leuven-Heverlee, Flanders, Belgium.
David AndesDepartment of Medicine, Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin, USA.
Patrick Van DijckLaboratory of Molecular Cell Biology, KU Leuven, Leuven-Heverlee, Flanders, Belgium Department of Molecular Microbiology, VIB, Leuven-Heverlee, Flanders, Belgium.ORCID 0000-0002-1542-897X
Mary Ann Jabra-RizkDepartment of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland, USA Department of Oncology and Diagnostic Sciences, Dental School, University of Maryland, Baltimore, Maryland, USA mrizk@umaryland.edu.
University of Maryland, Baltimore · USVIB-KU Leuven Center for Microbiology · BEUniversity of Wisconsin–Madison · US

Funding

Vesicle-mediated drug resistance of Candida albicans biofilmR01AI073289 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, MITCHELL, AARON P · 2008 to 2025
$7.9M
C. albicans and S. aureus Catheter Infections: Clinical Implications and TherapyR01AI130170 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI JABRA-RIZK, MARY ANN Y · 2017 to 2020
$1.5M
MOLECULAR BASIS OF VIRULENCE FACTORS OF ORAL FUNGAL SP.K22DE014424 · NIDCR · UNIVERSITY OF MARYLAND BALTIMORE · PI JABRA-RIZK, MARY ANN Y · 2002 to 2006
$601k
NIAID NIH HHS R01 AI073289NIAID NIH HHS R01 AI130170NIDCR NIH HHS K22 DE014424
6 · The paper itself

Abstract

Biofilm-associated polymicrobial infections, particularly those involving fungi and bacteria, are responsible for significant morbidity and mortality and tend to be challenging to treat. Candida albicans and Staphylococcus aureus specifically are considered leading opportunistic fungal and bacterial pathogens, respectively, mainly due to their ability to form biofilms on catheters and indwelling medical devices. However, the impact of mixed-species biofilm growth on therapy remains largely understudied. In this study, we investigated the influence of C. albicans secreted cell wall polysaccharides on the response of S. aureus to antibacterial agents in biofilm. Results demonstrated significantly enhanced tolerance for S. aureus to drugs in the presence of C. albicans or its secreted cell wall polysaccharide material. Fluorescence confocal time-lapse microscopy revealed impairment of drug diffusion through the mixed biofilm matrix. Using C. albicans mutant strains with modulated cell wall polysaccharide expression, exogenous supplementation, and enzymatic degradation, the C. albicans-secreted β-1,3-glucan cell wall component was identified as the key matrix constituent providing the bacteria with enhanced drug tolerance. Further, antibody labeling demonstrated rapid coating of the bacteria by the C. albicans matrix material. Importantly, via its effect on the fungal biofilm matrix, the antifungal caspofungin sensitized the bacteria to the drugs. Understanding such symbiotic interactions with clinical relevance between microbial species in biofilms will greatly aid in overcoming the limitations of current therapies and in defining potential new targets for treating polymicrobial infections. IMPORTANCE: The fungus Candida albicans and the bacterium Staphylococcus aureus are important microbial pathogens responsible for the majority of infections in hospitalized patients and are often coisolated from a host. In this study, we demonstrated that when grown together, the fungus provides the bacterium with enhanced tolerance to antimicrobial drugs. This process was mediated by polysaccharides secreted by the fungal cell into the environment. The biofilm matrix formed by these polysaccharides prevented penetration by the drugs and provided the bacteria with protection. Importantly, we show that by inhibiting the production of the fungal polysaccharides, a specific antifungal agent indirectly sensitized the bacteria to antimicrobials. Understanding the therapeutic implications of the interactions between these two diverse microbial species will aid in overcoming the limitations of current therapies and in defining new targets for treating complex polymicrobial infections.

Indexed as

Drug ToleranceMicrobial InteractionsAnti-Bacterial AgentsBiofilmsCandida albicansMicrobial ViabilityMicroscopy, ConfocalStaphylococcus aureusTime-Lapse ImagingAnti-Bacterial Agents

Identifiers

PMID27729510
PMCPMC5061872
OpenAlexW2530495088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.